Winton Group’s Zhengye Biotechnology Holding ZYBT Stock Holding History

Winton Group’s Portfolio ZYBT Stock Details ZYBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-12,730	Closed	-$8.62K	–	1580
2026 Q2	$8.62K	Sell	12,730 -20,659	-62%	-$18.5K	﹤0.01%	1137
2026 Q1	$31.2K	Sell	33,389 -29,908	-47%	-$28K	﹤0.01%	1075
2025 Q4	$72.8K	Buy	63,297 +41,750	+194%	+$92.5K	﹤0.01%	888
2025 Q3	$56.5K	Buy	+21,547	New	+$149K	﹤0.01%	696

Other funds holding ZYBT

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return

Winton Group's ZYBT Position: Q3 2026 in Review

Winton Group sold out of Zhengye Biotechnology Holding (ZYBT) in Q3 2026, closing a stake of 12,730 shares — an estimated $8.62K sold.

Winton Group first reported a position in ZYBT in Q3 2025 and held it in 4 quarters. The position peaked at $72.8K in Q4 2025. 4 funds tracked by Wall St. Rank hold ZYBT as of Q3 2026.

Winton Group reported no remaining Zhengye Biotechnology Holding position as of Q3 2026 after selling out during the quarter.
Winton Group sold 12,730 Zhengye Biotechnology Holding shares in Q3 2026, an estimated $8.62K.
Winton Group first reported a position in Zhengye Biotechnology Holding in Q3 2025 and held it in 4 quarters.
Winton Group's Zhengye Biotechnology Holding position peaked at $72.8K in Q4 2025.
4 funds tracked by Wall St. Rank held Zhengye Biotechnology Holding as of Q3 2026.

Based on Winton Group's 13F filing for Q3 2026, filed 12 Nov 2026.